Home > Drugs A – Z > Temsirolimus (By injection)

Temsirolimus (By injection)

Treats advanced kidney cancer.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Temsirolimus injection is used to treat advanced kidney cancer. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Temsirolimus is an antineoplastic (cancer medicine). This medicine is to be given only by or under the direct supervision of a doctor… Read more
Brand names include
Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Renal cell carcinoma (RCC) is a highly vascular type of kidney cancer arising in the epithelial elements of the nephrons. The most common histological subtype of RCC is clear cell carcinoma (approximately 75% of cases). RCC is often asymptomatic until it reaches a late stage. In England and Wales, kidney cancer is the eighth most common cancer in men and the fourteenth most common in women. Of those diagnosed with RCC in England and Wales, about 44% live for at least 5 years after initial diagnosis and about 40% for at least 10 years. However, prognosis following diagnosis of metastatic disease is poor, and only about 10% of people diagnosed with stage IV RCC live for at least 5 years after diagnosis.

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis

BACKGROUND: Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and temsirolimus are now approved by regulatory agencies and have been widely investigated among various types of solid tumors, but the risk of fatal adverse events (FAEs) with these drugs is not well defined.

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data

BACKGROUND: Two mTOR inhibitors, TEM and EVE, proved to be active in mRCC but have never been compared in a prospective trial. We aimed to compare their effectiveness in mRCC patients previously treated with a vascular endothelial growth factor receptor tyrosine kinase inhibitor, and performed a systematic review and meta-analysis of available evidence.

See all (23)

Summaries for consumers

Ibrutinib (trade name: Imbruvica) for mantle cell lymphoma: Overview

The drug ibrutinib (trade name: Imbruvica) has been approved in Germany since October 2014 for the treatment of mantle cell lymphoma in adults.

Targeted drug therapy for advanced kidney cancer

Cancer of the kidney is an important health problem with over 15,000 deaths in North America annually. Kidney cancer in adults that has spread or is too advanced for surgery is incurable and is resistant to conventional chemotherapy drugs. Drugs that affect the body's immune system have been standard care in the past two decades but have been associated with unpleasant side effects and poor results in most patients. Recent advances in understanding the molecular biology of kidney cancer have resulted in the development of drugs that target known molecular pathways (targeted therapy). This review critically examines reports of clinical trials that have directly compared the new targeted "designer" drugs with previous standard therapies for this condition, to see if these drugs could be considered an advance in care.

Renal Cell Cancer Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of renal cell cancer.

PubMed Health Blog...

read all...